# Trends in Cannabis Urine Drug Screen Testing in Colorado’s Largest Health System > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-urine-drug-screen-testing-colorado-health-system/ > **Published:** 2026-04-10T06:07:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:26:08-04:00 > **Clinical Summary:** Explore cannabis urine drug screen testing trends and disparities in Colorado's largest health system after legalization. --- CED Clinical Relevance  #71Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic Cannabis TestingHealthcare DisparitiesDrug ScreeningPolicy ImpactCohort Study Journal Journal of [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) Study Type Cohort Population Human participants Why This Matters This study provides critical insight into how [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) affects healthcare testing practices and reveals concerning demographic disparities in who gets tested. Understanding these patterns is essential for developing equitable clinical protocols around cannabis screening. Clinical Summary This retrospective cohort study analyzed 15 years of electronic medical record data from Colorado’s largest health system (2008-2022) to examine cannabis urine drug screening trends after recreational legalization. Cannabis positivity rates among tested patients rose from 14% to 30% between 2008-2015, then plateaued, while overall testing rates declined five-fold from 0.25% to 0.04% of visits. The study revealed significant demographic disparities, with younger patients, males, and individuals identifying as Black, Hispanic, or American Indian being disproportionately more likely to undergo cannabis testing. The observational design limits causal inferences about the relationship between policy changes and testing patterns. Dr. Caplan’s Take “These demographic disparities in testing patterns are deeply concerning and suggest potential bias in clinical decision-making around cannabis screening. The plateau in positivity rates after 2015 likely reflects population-level normalization of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) rather than changes in testing sensitivity.” Clinical Perspective 🧠 Clinicians should critically examine their own cannabis testing practices for potential demographic bias and ensure testing decisions are based on clear clinical indications rather than implicit assumptions. Healthcare systems need standardized, evidence-based protocols for when cannabis testing is clinically warranted to reduce disparities and improve care equity. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Trends%20in%20cannabis%20urine%20drug%20screen%20testing%20in%20Colorado%27s%20largest%20health%20system...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41772740/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41772740/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Trends%20in%20cannabis%20urine%20drug%20screen%20testing%20in%20Colorado%27s%20largest%20health%20system...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41772740/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41772740/](https://pubmed.ncbi.nlm.nih.gov/41772740/) Table of Contents - [FAQ](#FAQ)[How has cannabis legalization affected urine drug screen positivity rates in Colorado?](#How_has_cannabis_legalization_affected_urine_drug_screen_positivity_rates_in_Colorado) - [Are healthcare providers ordering fewer cannabis urine drug screens since legalization?](#Are_healthcare_providers_ordering_fewer_cannabis_urine_drug_screens_since_legalization) - [Which patient populations are more likely to receive cannabis urine drug screening?](#Which_patient_populations_are_more_likely_to_receive_cannabis_urine_drug_screening) - [Should the high positivity rates change how I interpret cannabis urine drug screens?](#Should_the_high_positivity_rates_change_how_I_interpret_cannabis_urine_drug_screens) - [What are the clinical implications of these cannabis testing trends for patient care?](#What_are_the_clinical_implications_of_these_cannabis_testing_trends_for_patient_care) - [Related](#Related) ## FAQ #### How has cannabis legalization affected urine drug screen positivity rates in Colorado? Cannabis positivity rates among urine drug screens doubled from 14% in 2008 to 30% in 2015, then plateaued. This dramatic increase coincided with Colorado’s [recreational cannabis](https://cedclinic.com/tennessee-medical-cannabis-program-debate-2026/) legalization timeline, suggesting legalization contributed to higher [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) among tested patients. #### Are healthcare providers ordering fewer cannabis urine drug screens since legalization? Yes, the proportion of healthcare visits that included cannabis testing declined significantly from 0.25% to 0.04% between 2008 and 2022. This suggests providers may be ordering cannabis screens less frequently, possibly due to changing attitudes toward cannabis use following legalization. #### Which patient populations are more likely to receive cannabis urine drug screening? Younger patients, males, and individuals identifying as Black, Hispanic, or American Indian were significantly more likely to be tested compared to their counterparts. These disparities raise important questions about potential bias in clinical decision-making around drug screening practices. #### Should the high positivity rates change how I interpret cannabis urine drug screens? With 30% of cannabis screens now testing positive, clinicians should consider the [clinical context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) and necessity of testing more carefully. The high positivity rate suggests cannabis use has become more prevalent, making positive results less diagnostically specific for identifying problematic use patterns. #### What are the clinical implications of these cannabis testing trends for patient care? Providers should be aware of potential demographic biases in their testing practices and ensure cannabis screening is clinically indicated rather than routine. The plateau in positivity rates and decreased testing frequency may reflect evolving clinical approaches to cannabis in healthcare settings where it’s legal. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [New Clinical Insights on Cannabis and Patient Outcomes](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) Discover recent clinical findings on cannabis use and its effects on patient health outcomes. [Read More](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) New Studies Illuminate Health Effects of Cannabis Use – NUG Magazine Explore emerging research highlighting the health impacts of cannabis consumption. Explore Studies [Treating Cannabis Addiction and Withdrawal: Latest Clinical Data](https://cedclinic.com/treating-cannabis-addiction-and-withdrawal-latest-clinical-data/) Review the latest clinical data on approaches to cannabis addiction and withdrawal treatment. [Learn More](https://cedclinic.com/treating-cannabis-addiction-and-withdrawal-latest-clinical-data/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).